Analysis Group Provides Economic Expertise in European Commission Investigation of CSL Vifor

June 3, 2025

Analysis Group was retained on behalf of the global pharmaceutical company CSL Vifor in a European Commission (EC) investigation. CSL Vifor was alleged to have restricted competition by illegally disparaging a competitor, Pharmacosmos, which manufactures Monofer, an intravenous iron treatment that competes with CSL Vifor's Ferinject. The EC opened an investigation under Article 102 to determine whether CSL Vifor used its dominant position in the market to harm its competitor’s uptake in the European Economic Area.

An Analysis Group team led by Vice President Joshua White provided economic support during the investigation, including analyzing relevant market definition, determinants of competition, and commercial success. As part of the resolution of the investigation, CSL Vifor proposed several commitments to address the Commission’s preliminary concerns and entered into a commercial settlement with Pharmacosmos. CSL Vifor’s proposed commitments were accepted by the EC.